HIV, Stable ART
Conditions
Keywords
HIV, ART
Brief summary
To assess the safety and tolerability of ALT-803, as well as, the potential efficacy of ALT-803 in HIV
Detailed description
This is an open-label, single-arm intra-patient dose escalating pilot study of ALT-803, a recombinant human super agonist interleukin-15 (IL-15) complex with an expansion cohort at the maximum tolerated dose (MTD). The primary aim is to investigate the safety and tolerability of ALT-803 in HIV-infected people receiving potent and optimized antiretroviral therapy. All infusions will occur on a Monday. Subjects will be monitored for 24 hours after the first infusion and then for 6 hours after each subsequent infusion, provided no unacceptable toxicity.
Interventions
DRUGALT-803
Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
Sponsors
University of Minnesota
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. HIV-1 infected adults aged 18 years or over. 2. Stable ART for at least 36 months 3. Screening plasma HIV RNA levels below level of quantification (\<40 to \<50 copies RNA/mL depending on the assay) ≥ 2 years (a single measurement above the level of detection but \< 100-200 copies/ml will be allowed) 4. Screening CD4 count ≥500 cells/mm3 5. Laboratory tests performed within 14 days of study enrollment: 1. WBC ≥ 3000/mm3 2. Platelets ≥ 50,000/mm3 \[Patients may be transfused to meet this requirement\] 3. Hemoglobin ≥ 8 g/dL (\>80g/L) \[Patients may be transfused to meet this requirement\] 4. Calculated glomerular filtration rate (GFR) \>45 mL/min/1.73m2 5. Total bilirubin ≤ 2.0 X upper limit of institutional normal (ULN) 6. AST, ALT, ALP ≤ 2.0 X ULN 6. Adequate pulmonary function without any clinical sign of severe pulmonary dysfunction. PFTs \> 50% of predicted if symptomatic or prior known impairment. 7. Ability to be off prednisone and other immunosuppressive drugs for at least 14 days before first dose of study drug 8. Women of child bearing potential and men with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy 9. Voluntary written consent
Exclusion criteria
1. Active infection other than HIV currently requiring systemic antimicrobial therapy 2. Previously treated on this study or received previous ALT-803 3. Latent TB infection or active TB disease prior to completing a standard regimen of anti-TB therapy 4. Active fungal infection requiring systemic antifungal therapy 5. Active or recurrent herpes or varicella-zoster virus infection requiring treatment (or chronic suppression) 6. Chronic hepatitis B or C 7. Planning or current pregnancy or breastfeeding 8. Intended modification of antiretroviral therapy in the next 24 weeks 9. NYHA (New York Heart Association) Class III or IV heart failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, or other clinical signs of severe cardiac dysfunction 10. Symptomatic congestive heart failure, unstable angina pectoris, or Myocardial infarction within 6 months prior to screening 11. Marked baseline prolongation of QT/QTc interval (e.g. demonstration of a QTc interval greater than 500 milliseconds) 12. History or evidence of uncontrollable CNS disease 13. Prior organ allograft or allogeneic transplantation 14. On-going chronic systemic or regular inhaled corticosteroid use or other immunosuppressive therapy (a history of mild asthma not requiring therapy is eligible) 15. Psychiatric illness/social situations that would limit compliance with study requirements 16. Other illness that in the opinion of the investigator would exclude the patient from participating in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assess the safety and tolerability of ALT-803 in HIV-infected subjects | 4 weeks | Safety and tolerability is determined by the incidence of adverse events, size of the inducible reservoir as estimated using the TILDA assay |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess the impact of ALT-803 on the size of the inducible reservoir, | 4 weeks | Assess the impact of ALT-803 on the size of the inducible reservoir, as estimated using the TILDA assay, in total CD4+ T cells and memory subsets |
Countries
United States
Outcome results
None listed